Global Cannabinoid Research Center

Referring to the termination of grants for research related to issues involving racial minorities, the judge said he had in four decades on the bench "never seen a record where racial discrimination was so palpable." BOSTON, June 16 (Reuters) - A federal judge in Boston on Monday said the termination of National Institutes of Health grants for research on diversity-related topics by President Donald Trump's administration was "void and illegal," and accused the government of discriminating against racial minorities and LGBT people.
U.S. District Judge William Young during a non-jury trial said the NIH violated federal law by arbitrarily canceling more than $1 billion in research grants because of their perceived connection to diversity, equity and inclusion initiatives.

Young said he was reinstating grants that had been awarded to organizations and Democratic-led states that sued over the terminations. And the judge indicated that as the case proceeds he could issue a more sweeping decision.

"This represents racial discrimination and discrimination against America's LGBTQ community," said Young, an appointee of Republican former President Ronald Reagan. "Any discrimination by our government is so wrong that it requires the court to enjoin it and at an appropriate time, I'm going to do it."

Referring to the termination of grants for research related to issues involving racial minorities, the judge said he had in four decades on the bench "never seen a record where racial discrimination was so palpable."

"You are bearing down on people of color because of their color," the judge said, referring to Trump's administration. "The Constitution will not permit that."

Judge deems Trump's National Institutes of Health grant cuts illegal "This represents racial discrimination and discrimination against America's LGBTQ community," said the judge, an appointee of Republican former President Ronald Reagan.

Read the study

Patterns of Cannabis Use Post-Legalization in California: A Closer Look at the “Impact 64” Study PrePrint June 9, 2025:

In the newly published study, Cannabis Use in California Following Legalization of Recreational Use by Hill et al. (2025), the authors deliver one of the most comprehensive state-wide assessments of cannabis consumption patterns since the enactment of Proposition 64 in California. Published in Cannabis and Cannabinoid Research, the study leverages data from the Impact 64 cohort to provide nuanced insights into post-legalization cannabis behavior among adults aged 21 and older.

Analyzing responses from over 15,000 census-weighted participants surveyed between December 2022 and February 2023, the study found that 37% reported current use (within the past three months), with a striking 38% of these users identifying as very frequent users (multiple times per day). The data reveals that high-frequency users tend to be male, less educated, and lower-income—a pattern echoing broader public health concerns about disparities in substance use. Most users consume multiple products—primarily inhaled flower (80%), vapes (66%), and edibles (61%)—obtained mainly from dispensaries perceived to be licensed (94%).

Home use dominates (93%), and motivations for consumption extend beyond recreation, including creativity (45%) and co-use with alcohol (36%). Encouragingly, over three-quarters of users report improved mental and emotional health, although the internet and social circles remain the primary sources of cannabis information.

Despite 78% of users feeling comfortable discussing use with their doctors, only 66% believe their physicians are aware of their recreational use, spotlighting a critical gap in clinical communication and education.

This study not only quantifies post-legalization usage but also highlights ongoing challenges, including equity in health education, clinical dialogue, and informed use.

The ECS is not a norm in dispensary-level consumer education.

-Mike Robinson, The Researcher OG

Genevieve's Dream CBGa is now an asset of Nanobles Corp., the corporate owner of the Global Cannabinoid Research Center. We seek a Corp to Corp Joint Venture with brand ownership potential for a partner with at least 5 years of experience in CPG, any Farm must be owned vs. leased, all soil to oil operations will be inspected before any contracts.

Needless to say, we've had our issues with inexperienced partners who are not capable of scaling this beautiful brand up to its full potential. I'm just a Dad on Father's Day today, I'm a researcher - I'm not a go-to-market type of guy.
But with the right team, the potential is incredible. I'm ready to relinquish operational control, but only to a team with a proven history and a legitimate operation that we can verify.

The correct entity could end up with a Joint Venture that leans their way in terms of majority ownership. We've had numerous headaches with immature members of the industry (including myself at times) that I feel I've failed my girl by being too eager without putting stipulations in place on who could be involved.

This is the Dream, the face of CBG If you've got a solid operation or know of one that needs a brand with a MAJOR HOOK? Get in contact!

-Mike Robinson, Genevieve's Daddy and founder of The Global Cannabinoid Researcher Center, CEO of Nanobles Corporation, and creator of Genevieve's Dream formulations. She owns her own dream. 🎠❤🎠

One day, I showed up and gave Genevieve Cannabis Oils. She wasn't doing well, and the report was that she couldn't go to school without a UCLA clearance due to the number of grand mal seizures she had. I came the next day and found a bright, smiling Genevieve who had just returned from what I think was the first day of school; it was nothing short of incredible. Focus on positivity, focus on plant-based solutions for a synthetic world that forces us to feed our bodies right, to learn about our ECS, and find ways to stay alive through times of chaos and more. -Mike Robinson, The Researcher OG

Email To GCRC: Academia Medicine (ISSN: 2994-435X) has recently launched a Special Issue on the topic "War and Health", guest edited by Prof. Luca Ansaloni ( University of Pavia, Pavia, Italy). We recommend reading the Editorial Article "No Health Without Peace," which outlines some of the key reasons this topic is of such importance.

The Special Issue focuses on the health consequences of armed conflicts, aiming to cover both their immediate and long-term effects on people. This issue welcomes scientific contributions, including new discoveries, research, reviews, and discussions about the impact of war on health (read more here). Manuscripts can be in the form of full-length research articles, reviews, or short communications and should be submitted by September 30, 2025.

By contributing to this special issue, your work will reach a broad audience through the Academia.edu network, a global platform for research sharing and networking, with a community of over 290 million users. Published articles in Academia.edu journals receive 4.6x more downloads than other comparable open-access journals in the first week, meaning your research will be read and cited by more top researchers in your field. -Academia Medicine

Survey Studies on your well-being and how cannabis plays a role right now are being worked on, as well as a way to get them to you.

-Mike Robinson, The Researcher OG

Study: Cannabidiol Reverses Schizophrenia-Related Brain Changes A review of "Cannabidiol reverses microglia activation and loss of parvalbumin interneurons and perineuronal nets in a mouse model of schizophrenia," a new study by Rodrigues da Silva et al., published online June 6, 20...

A review of "Cannabidiol reverses microglia activation and loss of parvalbumin interneurons and perineuronal nets in a mouse model of schizophrenia," a new study by Rodrigues da Silva et al., published online June 6, 2025, in Brain Research. Research paper

This work offers fresh insight into one of the most persistent challenges in psychiatry: finding effective treatments for the cognitive and negative symptoms of schizophrenia (SCZ). Despite decades of pharmacological progress, current antipsychotics largely fail to address these symptoms, which are the strongest predictors of long-term disability in SCZ patients. In this new paper, the authors present compelling evidence that cannabidiol (CBD) may reverse not only cognitive deficits but also key cellular and neuroinflammatory hallmarks of SCZ, bringing us one step closer to novel, multi-targeted interventions for this complex disorder.

SCZ is now increasingly understood as a disorder of glutamatergic hypofunction, particularly involving N-methyl-D-aspartate receptors (NMDARs).

Read the entire Research Review & study on GCRC's website Nanobles.com

-Mike Robinson, GCRC Founder

How we process social cues — how we connect — depends on something deeper than we think. In many cases of autism spectrum disorder (ASD), it’s not just about behavior or wiring — it’s about a system that modulates how the brain interprets its own signals: the Endocannabinoid System (ECS). New research is now helping us understand how this system may hold powerful keys to improving social function in ASD.

The 2025 study “Activation of CB1R alleviates autism spectrum disorder-like behavior and synaptic impairments” provides compelling evidence that targeted activation of the CB1 receptor (CB1R) — one of the ECS’s most important receptors — can dramatically improve both social behaviors and synaptic health in ASD models. Using valproic acid (VPA)-exposed mice and CB1R knockout mice, researchers demonstrated that blocking CB1R eliminated the benefits of enhancing the body's endocannabinoids, specifically 2-AG and anandamide.

Conversely, activating CB1R not only rescued social deficits but also enhanced neuronal complexity, spine density, dendritic integrity, and the expression of key synaptic proteins. The study also uncovered that this CB1R-driven improvement involves the regulation of the Kir4.1 potassium channel, a mechanism tightly linked to synaptic plasticity.

This reinforces what I’ve studied and taught for years through ECS Balance Control: when the ECS is dysregulated, with low endocannabinoid levels, altered receptor function, and poor synaptic tone, the brain’s ability to adapt, process social information, and regulate emotions suffers. In ASD, these disruptions are well documented.

But targeted support of this system, through nutrition (omega-3s, polyphenols), exercise, and intelligent cannabinoid use, especially CBGa, which supports endocannabinoid synthesis and receptor balance, offers a new path forward. ECS Balance isn’t a cure — it’s the foundation that enables the brain to respond more effectively to all other interventions.

This study makes it clear: the more we understand and support the ECS, the more we unlock its potential to improve lives.

-Mike Robinson, GCRC Founder